KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer preliminary results from a Phase 1b study
Meds ship to your door with free shipping
While there are no definitive studies indicating adverse interactions, it is essential to consult with a healthcare provider before combining these substances
In case of any side effects, the ministry should be informed via the ADR side effects form available at www.cpd-pharma.ae or by calling 023201448, faxing 023201947, emailing [email protected] or using the toll-free number 80011111
PMID: 41326795
Actual pricing may vary based on formulation, dosage, delivery method, location, clinical oversight, availability, and other factors